Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade B 15.19 1.88% 0.28
VNDA closed up 1.88 percent on Friday, August 16, 2019, on 89 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical VNDA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 1.88%
NR7 Range Contraction 2.64%
NR7-2 Range Contraction 2.64%
Wide Bands Range Expansion 2.64%
NR7 Range Contraction 0.93%
Wide Bands Range Expansion 0.93%
1,2,3 Pullback Bullish Bullish Swing Setup 1.00%
180 Bullish Setup Bullish Swing Setup 1.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.00%

Older signals for VNDA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Biopharmaceutical Chemical Compounds Organic Compounds Oncology Chemotherapy Schizophrenia Central Nervous System Disorders Major Depressive Disorder Depression Pyridines Nausea Treatment Of Central Nervous System Disorders Treatment Of Major Depressive Disorder Vomiting Pruritus Sedatives Chemotherapy Induced Nausea Fanapt Iloperidone Insomnia
Is VNDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.44
52 Week Low 11.83
Average Volume 778,132
200-Day Moving Average 19.4408
50-Day Moving Average 14.0156
20-Day Moving Average 14.132
10-Day Moving Average 15.087
Average True Range 0.715
ADX 29.65
+DI 28.6576
-DI 15.9336
Chandelier Exit (Long, 3 ATRs ) 14.855
Chandelier Exit (Short, 3 ATRs ) 13.975
Upper Bollinger Band 16.7235
Lower Bollinger Band 11.5405
Percent B (%b) 0.7
BandWidth 36.67563
MACD Line 0.3747
MACD Signal Line 0.2789
MACD Histogram 0.0958
Fundamentals Value
Market Cap 681.39 Million
Num Shares 44.9 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -66.04
Price-to-Sales 4.05
Price-to-Book 4.81
PEG Ratio -2.09
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.93
Resistance 3 (R3) 15.88 15.59 15.80
Resistance 2 (R2) 15.59 15.40 15.61 15.76
Resistance 1 (R1) 15.39 15.29 15.49 15.44 15.72
Pivot Point 15.10 15.10 15.15 15.12 15.10
Support 1 (S1) 14.90 14.91 15.00 14.95 14.66
Support 2 (S2) 14.61 14.80 14.63 14.62
Support 3 (S3) 14.41 14.61 14.58
Support 4 (S4) 14.46